What to Expect on Your First Telehealth Peptide Visit

A first telehealth peptide consultation is not a 15-minute video chat. It is a structured clinical evaluation done in pieces — intake, labs, clinician review, prescription decision, and onboarding into monitored therapy. The pieces happen on different days, and that is intentional. Compressing them into a single appointment would skip steps that matter.

This is what to expect, in order, the first time.

Step 1: The intake form

The first thing a patient does is fill out an intake form. A good intake is long. It asks about:

• Current medications and recent changes
• Medical history, including thyroid history, pancreatitis history, gallbladder disease, eating disorder history, mental health history
• Family history of medullary thyroid carcinoma or MEN 2 (specifically relevant for GLP-1 candidates)
• Pregnancy status and family planning
• Current weight, height, weight history
• Reason for considering peptide therapy
• What the patient has tried before
• Allergies and prior reactions to medications

Patients sometimes find this length surprising compared to consumer health products that ask three questions and ship something. The length is the point. The intake is the screening tool. The clinician makes the prescription decision based on what is in the intake plus what comes back from labs. A short intake produces a thin clinical record, and a thin record produces unsafe prescribing.

Plan to spend 15 to 25 minutes on intake. Take it seriously. If something feels minor, include it anyway — let the clinician decide what is and is not relevant.

Step 2: Lab work

Most reputable prescribed peptide visit workflows require baseline labs. The clinician sends an order to a partner lab; the patient walks in or schedules a draw. Common baseline panels include:

• Comprehensive metabolic panel
• Lipid panel
• HbA1c (for metabolic protocols)
• Thyroid function (TSH, free T4)
• Lipase (for GLP-1 candidates)
• IGF-1 (for growth-hormone-releasing peptide candidates)

Some patients arrive with recent labs already in hand. If they are fresh enough — typically within the last 6 months and aligned with the clinician's required panel — the clinician can use them. Otherwise, fresh labs are part of the workflow.

Lab turnaround is the slowest single step. Most labs return results within 2 to 5 business days. Until the labs are back, the clinician is not making a prescription decision.

Step 3: Clinician evaluation

Once intake and labs are in, a licensed clinician reviews the case. This review is the actual peptide prescription consultation. Some programs do this entirely asynchronously — the clinician reads the file and writes notes; others schedule a video call.

What the clinician is doing during review:

• Confirming the patient does not have a contraindication
• Choosing whether peptide therapy is appropriate at all
• Choosing which peptide and which starting dose
• Setting the titration schedule
• Setting the follow-up lab cadence
• Writing the prescription, or declining

The clinician may message the patient with clarifying questions. A short back-and-forth at this stage is normal and is a sign the clinician is doing real work, not auto-approving.

If the clinician declines, the patient is told why. Common decline reasons include a contraindication that surfaced in intake, a lab finding outside acceptable range for the requested protocol, or a clinical judgment that the protocol is not the right fit. A program that never declines is not screening.

Step 4: Prescription and pharmacy

If the clinician approves, a prescription is written and sent to a licensed pharmacy. Compounded peptide medications are dispensed by 503A or 503B compounding pharmacies, depending on the formulation. The pharmacy ships the medication, syringes, and a sharps container to the patient's address.

What arrives in the first shipment varies by protocol but typically includes:

• The peptide vial(s) for the starting dose period
• Pre-measured syringes or insulin syringes for self-injection
• Alcohol prep pads
• A sharps container
• Written dosing instructions and storage guidance

Storage matters. Most peptides require refrigeration. The shipping is temperature-controlled, and the patient should refrigerate the medication immediately on arrival.

Step 5: The onboarding window

The first 30 days of therapy are the most clinician-touchpoint-intense. The patient is learning the injection routine, watching for side effects, and observing whether the dose is producing the expected signal.

A well-run telehealth peptide doctor workflow includes:

• A scheduled check-in around day 7 (tolerance, injection technique, any side effects)
• Async messaging available throughout — the patient can write any time
• A scheduled check-in around day 21 to 30 (signal of effect, tolerance, plan for the next dose step)
• A defined response window — the program states how fast the clinician will reply

The patient is not on their own during this window. They are in active conversation with the clinician.

What a first visit does not include

For clarity, here is what a first visit does not include:

• A physical examination. Telehealth peptide care does not include hands-on exam. The screening is intake-based and labs-based.
• An imaging study. If imaging is clinically indicated, the clinician refers the patient out.
• A guarantee. A clinician decides based on evaluation. The intake fee covers evaluation, not approval.
• Same-day medication. From intake to medication arriving is one to two weeks, on average.

Common mistakes patients make

A few patterns show up in patients who are new to prescribed peptides telehealth:

1. Rushing the intake. Underreporting medical history. The clinician cannot screen on what is not on the page.
2. Skipping labs. Trying to find a program that does not require labs. Those programs exist and are not the kind of program a careful patient should choose.
3. Asking for a specific peptide without a clinical reason. The clinician chooses the protocol based on the case. The patient can describe their goals; the clinician chooses the medicine.
4. Treating the intake fee like a co-pay. The fee covers evaluation. If the clinician declines, the evaluation still happened.
5. Disappearing after week 1. The first few check-ins are when dose adjustments matter most. Skipping them defeats the structure.

What "good" looks like at this stage

By the end of the first visit cycle, a patient should have:

• Baseline labs on file
• A clinician they have communicated with by message or video
• A prescription on file with a named pharmacy
• A starting dose, a titration plan, and a defined check-in cadence
• Clear instructions on what to report and how
• A timeline for the first follow-up labs

If any of those are missing, something has been skipped.

Closing

The first telehealth peptide consultation is more administrative than dramatic. There is no big reveal. There is intake, labs, review, prescription, and onboarding. Done well, it sets up six months or more of safer, better-monitored therapy than a once-every-six-weeks clinic appointment would.

If you are about to schedule your first visit, the most useful thing you can do is set aside 30 quiet minutes for the intake, gather any recent labs you already have, and write down your honest goals. The clinician takes it from there.